Skip to main content
. Author manuscript; available in PMC: 2006 Jul 4.
Published in final edited form as: J Immunother. 2005;28(6):517–524. doi: 10.1097/01.cji.0000177999.95831.7b

FIGURE 3.

FIGURE 3

A course of dexamethasone did not augment but also did not inhibit immunotherapy with ACT. A, Dexamethasone depleted double-positive thymocytes. After a course of dexamethasone, thymocytes were enumerated and FACS analysis was used to determine the frequency of CD4+CD8+ thymocytes. Double-positive thymocyte number was reduced in the groups treated with dexamethasone at a dose of 1 mg/kg (DEX, 1 mg) and at a dose of 10 mg/kg (DEX, 10 mg) compared with mice receiving no dexamethasone (NO DEX). B, Dexamethasone alone (DEX only) had minimal effect on the growth of untreated tumors (NO TX). C, Tumor-bearing mice were treated with adoptive transfer of activated pmel-1 cells, vaccination with rFPgp10025–33, and IL-2 (PFI). Groups were treated with a course of dexamethasone at a dose of 10 mg/kg (PFI-DEX 10) or at a dose of 1 mg/kg on days 2, 4, 6, 8, and 10 after cell transfer (PFI-DEX 1). Tumor treatment was not affected by dexamethasone.